SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-096296
Filing Date
2024-08-13
Accepted
2024-08-13 16:27:19
Documents
101
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q atai-20240630.htm   iXBRL 10-Q 3543983
2 EX-31.1 atai-ex31_1.htm EX-31.1 14520
3 EX-31.2 atai-ex31_2.htm EX-31.2 15818
4 EX-31.3 atai-ex31_3.htm EX-31.3 16588
5 EX-32.1 atai-ex32_1.htm EX-32.1 18378
6 GRAPHIC img106865109_0.jpg GRAPHIC 123973
  Complete submission text file 0000950170-24-096296.txt   18004081

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT atai-20240630.xsd EX-101.SCH 3207003
104 EXTRACTED XBRL INSTANCE DOCUMENT atai-20240630_htm.xml XML 3274409
Mailing Address 524 BROADWAY NEW YORK NY 10013
Business Address WALLSTRASSE 16 BERLIN 2M 10179 (617)-699-5876
ATAI Life Sciences N.V. (Filer) CIK: 0001840904 (see all company filings)

IRS No.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40493 | Film No.: 241201950
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)